ID   Ty-82
AC   CVCL_3220
SY   TY-82; TY82; Ty82
DR   DepMap; ACH-001676
DR   EGA; EGAD00001003117
DR   GEO; GSM577206
DR   JCRB; JCRB1330
DR   JCRB; NIHS0541
DR   Wikidata; Q54973446
RX   PubMed=1730520;
RX   PubMed=21447744;
RX   PubMed=24736545;
RX   PubMed=28203693;
RX   PubMed=29348827;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~30 hours (Note=Lot 02152010), ~53 hours (Note=Lot 09082016) (JCRB=JCRB1330).
CC   Sequence variation: Gene fusion; HGNC; 13575; BRD4 + HGNC; 29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT; Note=BRD4 exon 14 fused to NUTM1 exon 2 (PubMed=24736545; PubMed=28203693; PubMed=29348827).
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: JCRB; NIHS0541; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 9,11
ST   D5S818: 9,11
ST   D7S820: 12,13
ST   TH01: 6,9.3
ST   TPOX: 9,11
ST   vWA: 17,19
DI   NCIt; C45716; NUT carcinoma
DI   NCIt; C35718; Thymic undifferentiated carcinoma
DI   ORDO; Orphanet_443167; NUT midline carcinoma
DI   ORDO; Orphanet_99868; Thymic carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   22Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 15
//
RX   PubMed=1730520; DOI=10.1002/ijc.2910500216;
RA   Kuzume T., Kubonishi I., Takeuchi S., Takeuchi T., Iwata J.,
RA   Sonobe H., Ohtsuki Y., Miyoshi I.;
RT   "Establishment and characterization of a thymic carcinoma cell line
RT   (Ty-82) carrying t(15;19)(q15;p13) chromosome abnormality.";
RL   Int. J. Cancer 50:259-264(1992).
//
RX   PubMed=21447744; DOI=10.1158/0008-5472.CAN-10-3513;
RA   Schwartz B.E., Hofer M.D., Lemieux M.E., Bauer D.E., Cameron M.J.,
RA   West N.H., Agoston E.S., Reynoird N., Khochbin S., Ince T.A.,
RA   Christie A.L., Janeway K.A., Vargas S.O., Perez-Atayde A.R., Aster J.C.,
RA   Sallan S.E., Kung A.L., Bradner J.E., French C.A.;
RT   "Differentiation of NUT midline carcinoma by epigenomic
RT   reprogramming.";
RL   Cancer Res. 71:2686-2696(2011).
//
RX   PubMed=24736545; DOI=10.1158/0008-5472.CAN-13-2658;
RA   Wang R.-R., Liu W., Helfer C.M., Bradner J.E., Hornick J.L.,
RA   Janicki S.M., French C.A., You J.-X.;
RT   "Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives
RT   neoplastic transformation in NUT midline carcinoma.";
RL   Cancer Res. 74:3332-3343(2014).
//
RX   PubMed=28203693; DOI=10.1093/annonc/mdw686;
RA   Lee J.-K., Louzada S., An Y., Kim S.Y., Kim S., Youk J., Park S.,
RA   Koo S.H., Keam B., Jeon Y.K., Ku J.-L., Yang F., Kim T.M., Ju Y.S.;
RT   "Complex chromosomal rearrangements by single catastrophic
RT   pathogenesis in NUT midline carcinoma.";
RL   Ann. Oncol. 28:890-897(2017).
//
RX   PubMed=29348827; DOI=10.18632/oncotarget.22862;
RA   Stirnweiss A., Oommen J., Kotecha R.S., Kees U.R., Beesley A.H.;
RT   "Molecular-genetic profiling and high-throughput in vitro drug
RT   screening in NUT midline carcinoma-an aggressive and fatal disease.";
RL   Oncotarget 8:112313-112329(2017).
//